Literature DB >> 35165864

Role of NK Cells in Tumor Progression.

Iñigo Terrén1, Francisco Borrego2,3.   

Abstract

Natural Killer (NK) cells are effector lymphocytes with the ability to generate an antitumor response. NK cells encompass a diverse group of subsets with different properties and have the capacity to kill cancer cells by different means. However, tumor cells have developed several mechanisms to evade NK cell-mediated killing. In this chapter, we summarize some aspects of NK cell biology with the aim to understand the competence of these cells and explore some of the challenges that NK cells have to face in different malignancies. Moreover, we will review the current knowledge about the role of NK cells in tumor progression and describe their phenotype and effector functions in tumor tissues and peripheral blood from cancer patients. Finally, we will recapitulate several findings from different studies focused on determining the prognostic value of NK cells in distinct cancers.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  CD56; Cancer; NK cells; Prognosis; Solid tumors; TINK cells; TME; Tumor evasion; Tumor microenvironment; Tumor-infiltrating lymphocytes

Mesh:

Year:  2022        PMID: 35165864     DOI: 10.1007/978-3-030-91311-3_6

Source DB:  PubMed          Journal:  Exp Suppl        ISSN: 1664-431X


  103 in total

1.  Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide.

Authors:  Ivraym B Barsoum; Thomas K Hamilton; Xin Li; Tiziana Cotechini; Ellen A Miles; D Robert Siemens; Charles H Graham
Journal:  Cancer Res       Date:  2011-10-17       Impact factor: 12.701

2.  TGF-β affects development and differentiation of human natural killer cell subsets.

Authors:  David S J Allan; Basya Rybalov; Génève Awong; Juan Carlos Zúñiga-Pflücker; Hernan D Kopcow; James R Carlyle; Jack L Strominger
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

3.  Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance.

Authors:  Galit Alter; Stephanie Jost; Suzannah Rihn; Laura L Reyor; Brian E Nolan; Musie Ghebremichael; Ronald Bosch; Marcus Altfeld; Georg M Lauer
Journal:  J Hepatol       Date:  2010-12-17       Impact factor: 25.083

4.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.

Authors:  Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Mingyi Chen; Rachel C Smith; Takeshi Hagino; Jessica Perez-Cunningham; Gail D Sckisel; Shiro Urayama; Arta M Monjazeb; Ruben C Fragoso; Thomas J Sayers; William J Murphy
Journal:  J Immunol       Date:  2015-09-11       Impact factor: 5.422

5.  Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC.

Authors:  Mirna Balsamo; Claudia Manzini; Gabriella Pietra; Federica Raggi; Fabiola Blengio; Maria Cristina Mingari; Luigi Varesio; Lorenzo Moretta; Maria Carla Bosco; Massimo Vitale
Journal:  Eur J Immunol       Date:  2013-08-05       Impact factor: 5.532

6.  Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.

Authors:  Fahmin Basher; Emily K Jeng; Hing Wong; Jennifer Wu
Journal:  Oncotarget       Date:  2016-01-05

7.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.

Authors:  Jan P Böttcher; Eduardo Bonavita; Probir Chakravarty; Hanna Blees; Mar Cabeza-Cabrerizo; Stefano Sammicheli; Neil C Rogers; Erik Sahai; Santiago Zelenay; Caetano Reis e Sousa
Journal:  Cell       Date:  2018-02-08       Impact factor: 41.582

Review 8.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

9.  PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.

Authors:  Asma Beldi-Ferchiou; Marion Lambert; Stéphanie Dogniaux; Frédéric Vély; Eric Vivier; Daniel Olive; Stéphanie Dupuy; Frank Levasseur; David Zucman; Céleste Lebbé; Damien Sène; Claire Hivroz; Sophie Caillat-Zucman
Journal:  Oncotarget       Date:  2016-11-08

10.  Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.

Authors:  Fahmin Basher; Payal Dhar; Xin Wang; Derek A Wainwright; Bin Zhang; Jeffrey Sosman; Zhe Ji; Jennifer D Wu
Journal:  J Hematol Oncol       Date:  2020-06-09       Impact factor: 17.388

View more
  1 in total

1.  In vivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation.

Authors:  Ane Orrantia; Enrique Vázquez-De Luis; Gabirel Astarloa-Pando; Iñigo Terrén; Ainhoa Amarilla-Irusta; Diego Polanco-Alonso; Carmen González; Alasne Uranga; Tomás Carrascosa; Juan J Mateos-Mazón; Juan C García-Ruiz; Sergio Callejas; Ana Quintas; Ana Dopazo; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  iScience       Date:  2022-09-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.